Recent Updates
Recently added Catalysts
BIO Positive Sentiment

Bio-Rad's Chief Operating Officer Andrew Last to Retire

Key Takeaway: Bio-Rad Laboratories announced the upcoming retirement of Chief Operating Officer Dr. Andrew Last, effective by early September 2024. Dr. Last, who joined the company in April 2019, will assist in the transition while a successor is identified. His leadership has been pivotal in driving operational improvements and navigating macroeconomic challenges, positioning Bio-Rad for continued growth. The company, known for its contributions to life sciences and clinical diagnostics, remains committed to innovation.
Price reaction · baseline $339.48 (2024-04-09 close) · hit after-hours · clean, no other BIO news in the window
day 0 close
-2.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Andrew Last has made invaluable contributions to Bio-Rad's leadership.
  • Significant progress in cost structure and supply chain improvements during his tenure.
  • Confidence in the team's accomplishments positioning the company for future growth.

Full Press Release Details

Bio-Rad's Chief Operating Officer Andrew Last to Retire
HERCULES, Calif.- April 10, 2024 -- Bio-Rad Laboratories, Inc. (NYSE BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024. Dr. Last will remain part of Bio-Rad's executive leadership team to ensure a smooth transition while the company conducts a search for his successor.
Dr. Last joined Bio-Rad in April of 2019 with over 30 years of experience in global operations management spanning the life sciences.
"Andy's extensive operations experience, technical acumen, and leadership abilities have been invaluable to Bio-Rad over the past five years," said Norman Schwartz, Bio-Rad President and CEO. "We have made significant progress on our transformational objectives, including cost structure, core processes, and supply chain improvements, while effectively navigating various macroeconomic challenges."
Dr. Last stated, "When I reflect on my tenure at Bio-Rad, I am most proud of the team we have built and the operations and management systems we have put in place. I am confident that these accomplishments have positioned Bio-Rad well for the next phase of its continued journey of transformation and growth."
Bio-Rad Laboratories, Inc. (NYSE BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

Frequently Asked Questions

When is Andrew Last retiring from Bio-Rad?

Dr. Andrew Last is set to retire by early September 2024.

What role does Andrew Last hold at Bio-Rad?

He is the Executive Vice President and Chief Operating Officer.

How long has Andrew Last worked at Bio-Rad?

He joined Bio-Rad in April 2019, totaling over five years.

What achievements did Andrew Last highlight?

He is proud of the team and operational systems developed during his tenure.

What is Bio-Rad's revenue for 2023?

Bio-Rad reported $2.7 billion in revenue for 2023.

Last updated: Apr 10, 2024